Literature DB >> 19708663

N-hydroxybenzimidazole inhibitors of the transcription factor LcrF in Yersinia: novel antivirulence agents.

Oak K Kim1, Lynne K Garrity-Ryan, Victoria J Bartlett, Mark C Grier, Atul K Verma, Gabriel Medjanis, Janice E Donatelli, Ann B Macone, S Ken Tanaka, Stuart B Levy, Michael N Alekshun.   

Abstract

LcrF, a multiple adaptational response (MAR) transcription factor, regulates virulence in Yersinia pestis and Yersinia pseudotuberculosis. In a search for small molecule inhibitors of LcrF, an acrylic amide series of N-hydroxybenzimidazoles was synthesized and the SAR (structure-activity relationship) was examined. Selected test compounds demonstrated inhibitory activity in a primary cell-free LcrF-DNA binding assay as well as in a secondary whole cell assay (type III secretion system dependent Y. pseudotuberculosis cytotoxicity assay). The inhibitors exhibited no measurable antibacterial activity in vitro, confirming that they do not target bacterial growth. These results demonstrate that N-hydroxybenzimidazole inhibitors, exemplified by 14, 22, and 36, are effective antivirulence agents and have the potential to prevent infections caused by Yersinia spp.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19708663      PMCID: PMC2778250          DOI: 10.1021/jm9006577

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  32 in total

Review 1.  Bacterial virulence as a target for antimicrobial chemotherapy.

Authors:  L E Alksne; S J Projan
Journal:  Curr Opin Biotechnol       Date:  2000-12       Impact factor: 9.740

2.  Small-molecule inhibitors specifically targeting type III secretion.

Authors:  R Nordfelth; A M Kauppi; H A Norberg; H Wolf-Watz; M Elofsson
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

3.  Antibiotic resistance-the problem intensifies.

Authors:  Stuart B Levy
Journal:  Adv Drug Deliv Rev       Date:  2005-07-29       Impact factor: 15.470

4.  MarA, SoxS and Rob function as virulence factors in an Escherichia coli murine model of ascending pyelonephritis.

Authors:  Paul Casaz; Lynne K Garrity-Ryan; David McKenney; Caroline Jackson; Stuart B Levy; S Ken Tanaka; Michael N Alekshun
Journal:  Microbiology       Date:  2006-12       Impact factor: 2.777

Review 5.  Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

Authors:  George H Talbot; John Bradley; John E Edwards; David Gilbert; Michael Scheld; John G Bartlett
Journal:  Clin Infect Dis       Date:  2005-01-25       Impact factor: 9.079

Review 6.  Regulation of virulence by members of the MarR/SlyA family.

Authors:  Damon W Ellison; Virginia L Miller
Journal:  Curr Opin Microbiol       Date:  2006-03-10       Impact factor: 7.934

7.  Structure of an OhrR-ohrA operator complex reveals the DNA binding mechanism of the MarR family.

Authors:  Minsun Hong; Mayuree Fuangthong; John D Helmann; Richard G Brennan
Journal:  Mol Cell       Date:  2005-10-07       Impact factor: 17.970

Review 8.  The bacterial injection kit: type III secretion systems.

Authors:  Luís J Mota; Guy R Cornelis
Journal:  Ann Med       Date:  2005       Impact factor: 4.709

9.  Yersinia pestis, the cause of plague, is a recently emerged clone of Yersinia pseudotuberculosis.

Authors:  M Achtman; K Zurth; G Morelli; G Torrea; A Guiyoule; E Carniel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

10.  Yersinia-induced apoptosis in vivo aids in the establishment of a systemic infection of mice.

Authors:  D M Monack; J Mecsas; D Bouley; S Falkow
Journal:  J Exp Med       Date:  1998-12-07       Impact factor: 14.307

View more
  26 in total

Review 1.  Chemical inhibitors of the type three secretion system: disarming bacterial pathogens.

Authors:  Miles C Duncan; Roger G Linington; Victoria Auerbuch
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

2.  MarA, SoxS and Rob of Escherichia coli - Global regulators of multidrug resistance, virulence and stress response.

Authors:  Valérie Duval; Ida M Lister
Journal:  Int J Biotechnol Wellness Ind       Date:  2013

Review 3.  On the road to structure-based development of anti-virulence therapeutics targeting the type III secretion system injectisome.

Authors:  Bronwyn J E Lyons; Natalie C J Strynadka
Journal:  Medchemcomm       Date:  2019-06-20       Impact factor: 3.597

4.  High-throughput screening of the virulence regulator VirF: a novel antibacterial target for shigellosis.

Authors:  Julie K Hurt; Thomas J McQuade; Anthony Emanuele; Martha J Larsen; George A Garcia
Journal:  J Biomol Screen       Date:  2010-03-17

5.  The bacterial type III secretion system as a target for developing new antibiotics.

Authors:  Andrew C McShan; Roberto N De Guzman
Journal:  Chem Biol Drug Des       Date:  2015-01       Impact factor: 2.817

6.  Synthetic Cyclic Peptomers as Type III Secretion System Inhibitors.

Authors:  Hanh Lam; Joshua Schwochert; Yongtong Lao; Tannia Lau; Cameron Lloyd; Justin Luu; Olivia Kooner; Jessica Morgan; Scott Lokey; Victoria Auerbuch
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 7.  Bioactive heterocycles containing endocyclic N-hydroxy groups.

Authors:  Reshma Rani; Carlotta Granchi
Journal:  Eur J Med Chem       Date:  2014-11-18       Impact factor: 6.514

8.  Inhibition of Pseudomonas aeruginosa ExsA DNA-Binding Activity by N-Hydroxybenzimidazoles.

Authors:  Anne E Marsden; Jessica M King; M Ashley Spies; Oak K Kim; Timothy L Yahr
Journal:  Antimicrob Agents Chemother       Date:  2015-11-16       Impact factor: 5.191

9.  Identification of a small-molecule inhibitor of bacterial AraC family activators.

Authors:  Jeff M Skredenske; Veerendra Koppolu; Ana Kolin; James Deng; Bria Kettle; Byron Taylor; Susan M Egan
Journal:  J Biomol Screen       Date:  2013-01-30

10.  Small molecules aimed at type III secretion systems to inhibit bacterial virulence.

Authors:  Lun K Tsou; Paul D Dossa; Howard C Hang
Journal:  Medchemcomm       Date:  2013-01-01       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.